Sep. 30 at 9:11 PM
$ARWR Another Potential Winner! Similar to
$CRNX my pick last week.
1. FDA accepted NDA;
2. PDUFA Nov 18, 2025 with no planned AdCom.
3. Pivotal PALISADE Phase 3: median TG ↓ ~78–80% at 10–12 months vs placebo (p<0.001); APOC3 ↓ up to 94%; reduced acute pancreatitis incidence; favorable safety with low discontinuation rates.
4. First drug for Arrowhead if approved.
Please do your own DD.
